CN103735736A - Preparation method of liver-soothing tablet and application - Google Patents
Preparation method of liver-soothing tablet and application Download PDFInfo
- Publication number
- CN103735736A CN103735736A CN201410024819.1A CN201410024819A CN103735736A CN 103735736 A CN103735736 A CN 103735736A CN 201410024819 A CN201410024819 A CN 201410024819A CN 103735736 A CN103735736 A CN 103735736A
- Authority
- CN
- China
- Prior art keywords
- liver
- energy dispersing
- medicine
- parts
- depressed liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a liver-soothing tablet, which contains active components prepared from the following raw materials in parts by weight: 5-7 parts of the fruit of Chinese wolfberry, 5-7 parts of cape jasmine, 5-7 parts of poria cocos, and 5-7 parts of the root of red-rooted salvia. A corresponding preparation method is adopted. The liver-soothing tablet prepared by the invention has the effects of nourishing liver and kidney, clearing heat, cooling blood, clearing damp, promoting dieresis, promoting circulation and removing stasis and is capable of protecting chemical liver injury, treating fatty liver and inhibiting proliferation of human neural glioma cell SF295.
Description
Technical field
The present invention relates to Chinese medicine preparation technical field, be specifically related to a kind of preparation method and application of the depressed liver-energy dispersing medicine.
Background technology
Along with the continuous improvement of China people living standard, the sickness rate of domestic hepatopathy raises year by year, comprises that the sickness rate of chemical liver injury, fatty liver etc. can be up to 20% left and right; At present, for hepatopathy, there is no desirable specific treatment medicine both at home and abroad.The large multiaction of existing conventional anti-hepatic medicine relaxes clinically, therapeutic domain limitation, and curative effect is not remarkable, and some medicine life-time service have damage to liver, should not be for the treatments of hepatopathy, some medicines also can produce toxic and side effects.For this reason, be badly in need of developing the needs that more health foods for the treatment of safely and effectively hepatopathy meet clinical treatment.
Prevalence is high, and relapse rate height is the main feature of hepatopathy, reflects that the demand in hepatosis treating medicine market is huge simultaneously.Health food is in hepatopathy medication market share critical role, because health food side effect is little, determined curative effect, is applicable to long-term prescription, has adapted to the easily feature of recurrence of hepatopathy, applies very extensive.
Summary of the invention
The object of the present invention is to provide a kind of preparation method and application of the depressed liver-energy dispersing medicine.
Technical scheme of the present invention is:
A depressed liver-energy dispersing medicine, its contained active component is prepared from by following raw materials in part by weight proportioning: Fructus Lycii 5-7 part, Fructus Gardeniae 5-7 part, Poria 5-7 part, Radix Salviae Miltiorrhizae 5-7 part.
The contained active component of above-mentioned the depressed liver-energy dispersing medicine is prepared from by following raw materials in part by weight proportioning: 6 parts of Fructus Lycii, 6 parts of Fructus Gardeniaes, 6 parts, Poria, 6 parts of Radix Salviae Miltiorrhizaes.
The preparation process of the depressed liver-energy dispersing medicine is: get Fructus Lycii, Fructus Gardeniae, Poria and the red rooted salvia of recipe quantity and mix, adding water 2 times, decocting collecting decoction, filter, it is 1.10-1.15 that filtrate is concentrated into relative density, and 65 ℃ of surveys are dry, be ground into dry extract, add adjuvant, make tablet.
In the preparation process of the depressed liver-energy dispersing medicine, amount of water, for 10 times of mixing medical material gross weight, decocts 2-3 hour for the first time, and amount of water, for mixing 8 times of water gagings of medical material gross weight, decocts 1-2 hour for the second time.
The application of the depressed liver-energy dispersing medicine in preparation protection chemical liver injury health food.
The application of the depressed liver-energy dispersing medicine in preparation treatment fatty liver health food.
The depressed liver-energy dispersing medicine suppresses the application in human glioma SF295 cell proliferation medicine in preparation.
Compared with prior art, the present invention has following beneficial effect:
1. pharmacological research finds that we have protection chemical liver injury, treatment fatty liver and suppress the effects such as human glioma cell SF295 propagation, and curative effect is reliable, and does not find toxic and side effects.We, because of to the pathogen and pathology of tcm of chemical liver injury, fatty liver with method for the treatment of analysis is accurate, compatibility is reasonable, have obtained significant curative effect in clinical treatment.
2. from theory of Chinese medical science, Fructus Lycii nourishing the liver and kidney in the depressed liver-energy dispersing medicine of the present invention, replenishing vital essence to improve eyesight, Fructus Gardeniae heat clearing away, pathogenic fire purging, removing heat from blood, has the effects such as hepatoprotective, function of gallbladder promoting, blood pressure lowering, calmness, hemostasis, detumescence, is usually used in treating the diseases such as icterohepatitis, bruise, hypertension, diabetes.Poria promoting diuresis to eliminate damp pathogen, invigorating the spleen for dissipating phlegm, mind tranquilizing and the heart calming, relieves internal heat anticancer.The effect of Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, lowering blood-fat and reducing weight, calming heart and tranquilizing mind, clearing heat for detumescence.Monarch drug in Fructus Lycii and the Fructus Gardeniae side of being in side, a benefit one is clear, has soothing the liver sensible effect, and Poria is ministerial drug, the merit that principal drug assistance is soothing the liver, Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, is adjuvant.Full side's nourishing the liver and kidney, clearing away heat and cooling blood, promoting diuresis to eliminate damp pathogen, blood circulation promoting and blood stasis dispelling again, have the effect of protection chemical liver injury and treatment fatty liver, and applicant also finds to suppress human glioma cell SF295 propagation.
This problem can be actively anti-hepatic generation and development effectively, this for improve hepatopathy patients existence and quality of life, protect the health of vast hepatopathy patients, and then raising productivity, significant and higher practical value.Because primary disease sickness rate is high, estimate, once marketing application, will produce good Social benefit and economic benefit.
4. Formulation of the present invention is reasonable, and compatibility is rigorous.
5. the present invention consists of dietotherapeutic Chinese crude drug, have no side effect, and low price.
The specific embodiment
Form by the following examples, foregoing of the present invention is described in further detail again, but this should be interpreted as to the scope of the above-mentioned theme of the present invention only limits to following example, all technology realizing based on foregoing of the present invention all belong to scope of the present invention.
1,, in conjunction with the specific embodiment, the present invention is further described as follows:
According to the form below, listed weight proportion takes raw material required for the present invention, unit: g
| ? | Fructus Lycii | Fructus Gardeniae | Poria | Radix Salviae Miltiorrhizae |
| Embodiment 1 | 500 | 700 | 500 | 700 |
| Embodiment 2 | 700 | 500 | 700 | 500 |
| Embodiment 3 | 600 | 600 | 600 | 600 |
| Embodiment 4 | 500 | 600 | 700 | 600 |
In the present invention, Fructus Lycii, Fructus Gardeniae, Poria and Radix Salviae Miltiorrhizae are pharmacopeia kind.
2, Preparation Example
The preparation of embodiment 1:
By upper table, get Fructus Lycii, Fructus Gardeniae, Poria and red rooted salvia also mix, add water 2 times, decoct, amount of water is 10 times of mixing medical material gross weight for the first time, decoct 2 hours, amount of water is for mixing 8 times of water gagings of medical material gross weight for the second time, decoct 2 hours collecting decoctions, filter, it is 1.10 that filtrate is concentrated into relative density, 65 ℃ of surveys, dry, be ground into dry extract, add again starch, mix homogeneously, with appropriate 80% ethanol moistening, soft material processed, crossing 30 mesh sieves granulates, dry in 70～80 ℃, with 60 mesh sieve granulate, tabletting, sugar coating, subpackage, outer package, censorship is qualified, obtain tablet finished product.
The preparation of embodiment 2:
By upper table, get Fructus Lycii, Fructus Gardeniae, Poria and red rooted salvia also mix, add water 2 times, decoct, amount of water is 10 times of mixing medical material gross weight for the first time, decoct 3 hours, amount of water is for mixing 8 times of water gagings of medical material gross weight for the second time, decoct 3 hours collecting decoctions, filter, it is 1.13 that filtrate is concentrated into relative density, 65 ℃ of surveys, dry, be ground into dry extract, add again starch, mix homogeneously, with appropriate 80% ethanol moistening, soft material processed, crossing 30 mesh sieves granulates, dry in 70～80 ℃, with 60 mesh sieve granulate, tabletting, sugar coating, subpackage, outer package, censorship is qualified, obtain tablet finished product.
3 preparations of embodiment:
By upper table, get Fructus Lycii, Fructus Gardeniae, Poria and red rooted salvia also mix, add water 2 times, decoct, amount of water is 10 times of mixing medical material gross weight for the first time, decoct 3 hours, amount of water is for mixing 8 times of water gagings of medical material gross weight for the second time, decoct 2 hours collecting decoctions, filter, it is 1.15 that filtrate is concentrated into relative density, 65 ℃ of surveys, dry, be ground into dry extract, add again starch, mix homogeneously, with appropriate 80% ethanol moistening, soft material processed, crossing 30 mesh sieves granulates, dry in 70～80 ℃, with 60 mesh sieve granulate, tabletting, sugar coating, subpackage, outer package, censorship is qualified, obtain tablet finished product.
The preparation of embodiment 4:
By upper table, get Fructus Lycii, Fructus Gardeniae, Poria and red rooted salvia also mix, add water 2 times, decoct, amount of water is 10 times of mixing medical material gross weight for the first time, decoct 2 hours, amount of water is for mixing 8 times of water gagings of medical material gross weight for the second time, decoct 2 hours collecting decoctions, filter, it is 1.10 that filtrate is concentrated into relative density, 65 ℃ of surveys, dry, be ground into dry extract, add again starch, mix homogeneously, with appropriate 80% ethanol moistening, soft material processed, crossing 30 mesh sieves granulates, dry in 70～80 ℃, with 60 mesh sieve granulate, tabletting, sugar coating, subpackage, outer package, censorship is qualified, obtain tablet finished product.
3, the experimentation that affects on mice chemical liver injury
3.1 laboratory animals: Kunming mouse, male, body weight 18-22g, Nanjing Medical University's Experimental Animal Center provides.
3.2 Experimental agents: press the preparation method preparation of above-described embodiment 3, obtain 1000, tablet, specification: 1g/ sheet (being equivalent to every containing crude drug 2.4g), the self-control of Shenzhen San Ye Bioisystech Co., Ltd, lot number: 20130512.
Dosage: according to the dose,equivalent ratio table > > converting by surface between < < humans and animals, every day, 70 kilograms of people's consumption was each 2, every day three times, it is 6 of every days, add up to 14.4g, every day, the consumption of every 20g mice was 14.4*0.0026=0.037g, because every 1g is 2.4g containing crude drug amount, the consumption that is every mice is 0.0156g tablet, for ease of administration, low dose of gavage 0.02g tablet, dosage and high dose difference gavage 0.04g and 0.08g in, be every day the tablet of every 20g mouse stomach be respectively 0.05g containing crude drug amount, 0.1g, 0.2g, press Mice Body restatement, low dosage, middle dosage and high dose are respectively 2.5g crude drug amount/kg, 5g crude drug amount/kg and 10g crude drug amount/kg.
Main agents: CCl
4fasten chemical reagent factory product in Hai Xin, before use with refining Oleum Arachidis hypogaeae semen dilution.Lot number: 1205012.Alanine aminotransferase (ALT) is measured test kit: Bioengineering Research Institute's product is built up in Nanjing, lot number: 20131029; Radix Asparagi door propylhomoserin aminotransferase (AST) is measured test kit: Bioengineering Research Institute's product is built up in Nanjing, lot number: 20131019.
3.3 experimentations:
3.3.1 select 50 of healthy mices, separate at random 10 as normal group, all the other 40 mices are divided into 4 groups at random: model group, high dose group, middle dosage group, low dose group, lumbar injection 0.1%CCl
410ml/kg modeling, wherein 4 dosage groups are by above-mentioned dosage gastric infusion, and Normal group and model group are to the water of same volume, and every morning 1 time, 30d, after fasting 18h, from the blood sampling of mice posterior orbit venous plexus, measures serum aminotransferase activity continuously; And get the content that liver homogenate is measured MDA, SOD, GSH-Px level, and get liver and fix through 10% formaldehyde, pathologic finding is made in HE dyeing.
3.3.2 adopt the statistical method of variance analysis, result shows, compare with normal group, model group Serum ALT, AST level significantly raise, difference has significance (P<0.01), give the present invention (2.5,5,10g/kg) group and all can significantly reduce ALT, the AST level raising in serum, difference has significance (P<0.01).In Table 1.
Table 1 the present invention is to CCl
4cause the impact (X ± s) of acute chemical hepatic injury model mice Serum ALT, AST
Note: compare * p<0.05**<0.01 with model group; With normal group, compare
△<0.05
△ △<0.01
3.3.3 the present invention is to CCl
4the impact that causes acute chemical hepatic injury mouse liver even slurry MDA, SOD, GSH-Px level shows, model group liver homogenate MDA level significantly raises, and SOD, GSH-Px level significantly reduce simultaneously, and difference has significance (P<0.01).The present invention who gives various dose all can significantly reduce the MDA level raising in liver homogenate, can improve liver homogenate SOD and GSH-Px level simultaneously, and difference has significance (P<0.05); Adopt Ridit analytical method, HE discoverys of dye, occurs in model group liver that the spot film piece that diffusivity distributes is downright bad, bridging necrosis, and hepatic sinusoid hyperemia is obvious, dispersivity cell infiltration.In the present invention, heavy dose of group all can alleviate extent of disease and degree, and cell infiltration is reduced.
3.4 the depressed liver-energy dispersing medicines have the good effect that prevents to chemical liver injury, can be used for preparation protection chemical liver injury health food.
4, the experimentation of blood fat reducing of the present invention:
Laboratory animal: Kunming mouse, male, body weight 18-22g, Nanjing Medical University's Experimental Animal Center provides.
Experimental agents: the same, Zhibituo, by Chengdu, buchu Jiu Hong pharmaceutical factory produces, and lot number is 0906211, specification: every dress 0.24g.High lipid food: 10% yolk powder, 1.2% cholesterol, 10% Adeps Sus domestica, 78% normal feedstuff.
Dosage: the same.
Main agents: T-CHOL (TC), triglyceride (TG), highly dense low lipoprotein cholesterol (HDL-C) and low density lipoprotein, LDL (LDL-C) are measured test kit, Beijing Zhong Sheng bio-engineering corporation product.
Experimentation: select 60 of healthy mices, separate at random 10 as normal group, all the other 50 mices, raise with high lipid food, normally drinks water, and modeling 14d, obtains model group.After model causes, be divided at random 5 groups: model group, high dose group, middle dosage group, low dose group, positive drug zhibituo group (340mg/kg), wherein 3 dosage groups, zhibituo groups are pressed above-mentioned dosage gastric infusion, and Normal group and model group are to the water of same volume, every morning 1 time, 30d, gets each Mus TC of hematometry, TG continuously, HDL-C, LDL-C, each is organized data and represents with means standard deviation, carries out t test between group.The results are shown in Table 2
The impact (n=10) of table 2. the present invention on Experimental Hyperlipemia Mouse Blood ester level
Note: compare * p<0.05**<0.01 with model group; With zhibituo group, compare
△<0.05
△ △<0.01
Conclusion: the present invention can reduce Experimental Hyperlipemia Mouse Blood ester level.
5, clinical research result
Clinical medicine: press the preparation method preparation of above-described embodiment 3, obtain 1000, tablet, the self-control of Shenzhen San Ye Bioisystech Co., Ltd, lot number: 20130512.
The routine patient of clinical observation 60, male 35 examples, female's 25 examples, age 40-65 year, the course of disease is the shortest 5 months, the longest 12 years, fat 46 examples of the bodily form, the history of being addicted to drink 21 examples, hypertension history 16 examples, History of Coronary Heart Disease 13 examples, take three every day, each 2.
Diagnostic criteria: (1) Western medicine diagnose standard is learned the Diagnosis of Fatty liver standard in > > with reference to the clinical liver-gallbladder disease of Ye Weifa chief editor < <.(2) tcm diagnosis standard is with reference to the < < disease of tcm Standardization of diagnosis and curative effect > > of State Administration of Traditional Chinese Medicine's issue, be divided into qi-deficiency type 10 examples, caused by hepatic stagnation qi stagnation 12 examples, liver gallbladder damp-heat type 10 examples, deficiency of kidney yin type 7 examples, type of deficiency of YIN leading to hyper activity of YANG 11 examples, expectorant silt interlocking type 10 examples.There is in various degree spiritlessness and weakness in most of patients, inappetence, and tiredness with no desire to speak, uncomfortable liver area, large loose stool is thin, dark tongue quality thick and greasy fur.
Curative effect judgement:
Cure: cardinal symptom disappears, hepatomegaly disappears or retraction, and hepatic region is without obvious tenderness or percussion pain, and liver function is normal, and ultrasonic echo figure and ultrasonogram are normal, and blood fat is tending towards normally or obviously improves weight loss.
Take a turn for the better: cardinal symptom disappears substantially, and hepatomegaly is recovered to some extent, and ultrasonoscopy is clearly better, and blood fat makes moderate progress, and body weight declines to some extent.
Invalid: symptom, sign, chemical examination, ultrasonoscopy and body weight are without changer.
The results are shown in Table 3
The observation of curative effect of table 3. the present invention to fatty liver patient
The present invention is through clinical practice, tool patient's the weak effect of right distending pain over the hypochondrium, abdominal distention that has clear improvement, and there is Weight-reducing and lipid-lowering, improve liver function, the effect for the treatment of fatty liver.In table, can find out medicine of the present invention, in 60 examples, curing number is 35 examples, and good revolution is 20 examples, and invalid is 5 examples, and total effective rate is 91.7%, in taking, has no adverse reaction.
6, the depressed liver-energy dispersing medicine suppresses the experimentation data of human glioma SF295 cell proliferation
6.1 experiment material
6.1.1 experiment cell strain: human glioma SF295 cell, Nanjing Medical University's laboratory cell bank, DMEM+10%FBS cellar culture.
6.1.2 Experimental agents
Drugs: the depressed liver-energy dispersing medicine of the present invention: press embodiment 3 method preparations, the self-control of Shenzhen San Ye Bioisystech Co., Ltd, lot number: 20130512.
Medicinal liquid liquid storage: take 100mg the depressed liver-energy dispersing medicine, be dissolved in 5ml dehydrated alcohol, 0.2 μ m filter filters, 500 μ l doff pipe subpackages ,-20 ℃ of storages, 0.2 μ m filter filters dehydrated alcohol in order to the use of matched group simultaneously.
6.1.3 experiment reagent
The Cat.No.12100-061Lot.No.758137 of DMEM(GIBCO company); Hyclone (Lot.No.100419 of Tian Hang bio tech ltd, Zhejiang); The NaHCO3(Shanghai Jiu Yi chemical reagent Cat.No.11810-033Lot.No.1088387 of company limited); Trypsin(AMRESCO company lot number: 2010/04); EDTA(AMRESCO company lot number: 2009/10); Penicillin G Sodium Salt(AMRESCO company lot number: 2010242); Streptomycin Sulfate(AMRESCO company lot number: 2010382); Dehydrated alcohol (Nanjing Chemistry Reagent Co., Ltd.'s lot number: 080310182); MTT (Biosharp lot number: 0793); The autogamy of PBS(laboratory);
6.1.4 experiment equipment
Lycra inverted microscope (German Leica model: DM1L); Visible-ultraviolet light microwell plate detector (U.S. MD company model: SPECTRA MAX190); CO2 incubator (FORMA model: 3111); (safe and sound company of Su Jing group manufactures model to super-clean bench: SW-CJ-ZFD); Pure water instrument (U.S. Spring company model: S/N020579); Accurate pipettor (French Gilson Inc model: P2); Electronic balance (German Sai Duolisi company limited model: BT323S); Full-automatic high-pressure autoclave (Japanese SANYO company model: MLS-3020); Table electrothermal air dry oven (Shanghai accurate experimental facilities company model: DHG9123A); Refrigerator (Siemens Company's model: KG18V21TI); Liquid nitrogen container (CBS model: 2001); Low speed centrifuge (Anting Scientific Instrument Factory, Shanghai's model: KA-1000); 0.2 μ m filter (MILLIPORE model: SLGP033RB); 10cm culture dish (NEST company), 96 well culture plates (NEST company); Cell counting count board; Centrifuge tube, pipet, Tips are some.
6.2 experimental technique
1) SF295 cell carries out cellar culture (10cm culture dish) with DMEM+10%FBS in 37 ℃, 5%CO2, when Growth of Cells is during to logarithmic (log) phase, collecting cell, discards culture fluid, PBS fine laundering 3 times, add 3ml0.25% trypsin-0.04%EDTA, after 37 ℃ of digestion 2min, add wherein 5ml complete medium neutralization reaction, after piping and druming cell, proceeded in centrifuge tube, the centrifugal 5min of 1000rpm, adjusts 3 * 104/ml of concentration of cell suspension.
2) cell kind is entered in 96 well culture plates, every hole adds cell suspension 180 μ l, culture plate put into cell culture incubator (37 ℃, 5%CO2) cellar culture.
3) according to Growth of Cells situation, generally grow to 50%-70%, add the depressed liver-energy dispersing medicine solution, continue to cultivate 24h.
4) after 24h, add 20 μ l MTT solution (5mg/ml, i.e. 0.5%MTT), continue to cultivate 4h.
5) after 4h, buckle method is removed supernatant, with absorbent paper, pats dry gently, and every hole adds 200 μ l dimethyl sulfoxide, puts low-speed oscillation 10min on shaking table, and crystal is fully dissolved.At enzyme-linked immunosorbent assay instrument 490nm place, measure the light absorption value in each hole.
6) background (do not add cell, only add culture fluid) is set simultaneously, control wells (the medicine dissolution medium of cell, same concentrations, culture fluid, MTT, dimethyl sulfoxide), sets 6 multiple holes for every group.
7) result represents the suppression ratio of cell with medicine:
Cell increment suppression ratio (%)=(control wells OD value-dosing holes OD value)/control wells OD value * 100%.Experiment repeats 3 times.
6.3 statistical disposition
Adopt correlation analysis and Student t check in Microsoft Excel2003 software, data represent with mean ± S.D..
6.4 experimental result
Statistical result showed after mtt assay experiment, with matched group comparison, when dosage reaches 5mg/ml, to SF295 cell inhibitory effect variant (P<0.05), dosage this difference when 10mg/ml has significance (P<0.01), has utmost point significant difference (P<0.001) when dosage reaches 15-20mg/ml.
Table 4 the depressed liver-energy dispersing medicine is on SF295 cell inhibitory effect impact research (X ± SD)
Note: with matched group comparison, * P<0.01; * P<0.001
6.5 experiment conclusion
The depressed liver-energy dispersing medicine can suppress SF295 cell proliferation, reduces the Growth of Cells number of SF295 cell, and this effect is dose dependent.
Claims (7)
1. a depressed liver-energy dispersing medicine, is characterized in that, its contained active component is prepared from by following raw materials in part by weight proportioning: Fructus Lycii 5-7 part, Fructus Gardeniae 5-7 part, Poria 5-7 part, Radix Salviae Miltiorrhizae 5-7 part.
2. the depressed liver-energy dispersing medicine as claimed in claim 1, is characterized in that, its contained active component is prepared from by following raw materials in part by weight proportioning: 6 parts of Fructus Lycii, 6 parts of Fructus Gardeniaes, 6 parts, Poria, 6 parts of Radix Salviae Miltiorrhizaes.
3. the depressed liver-energy dispersing medicine as claimed in claim 1 or 2, is characterized in that, the preparation process of the depressed liver-energy dispersing medicine is: get Fructus Lycii, Fructus Gardeniae, Poria and the red rooted salvia of recipe quantity and mix, add water 2 times, decoct, collecting decoction, filters, it is 1.10-1.15 that filtrate is concentrated into relative density, 65 ℃ of surveys, dry, pulverize into dry extract, add adjuvant, make tablet.
4. the depressed liver-energy dispersing medicine as claimed in claim 4, is characterized in that in the preparation process of the depressed liver-energy dispersing medicine that amount of water for the first time, for mixing 10 times of medical material gross weight, decocts 2-3 hour, and amount of water, for mixing 8 times of water gagings of medical material gross weight, decocts 1-2 hour for the second time.
5. the application of the depressed liver-energy dispersing medicine as claimed in claim 1 or 2 in preparation protection chemical liver injury health food.
6. the application of the depressed liver-energy dispersing medicine as claimed in claim 1 or 2 in preparation treatment fatty liver health food.
7. the depressed liver-energy dispersing medicine as claimed in claim 1 or 2 suppresses the application in human glioma SF295 cell proliferation medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410024819.1A CN103735736B (en) | 2014-01-20 | 2014-01-20 | A kind of preparation method and application of the depressed liver-energy dispersing medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410024819.1A CN103735736B (en) | 2014-01-20 | 2014-01-20 | A kind of preparation method and application of the depressed liver-energy dispersing medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103735736A true CN103735736A (en) | 2014-04-23 |
| CN103735736B CN103735736B (en) | 2016-05-04 |
Family
ID=50492851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410024819.1A Active CN103735736B (en) | 2014-01-20 | 2014-01-20 | A kind of preparation method and application of the depressed liver-energy dispersing medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103735736B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104474171A (en) * | 2014-11-17 | 2015-04-01 | 辛振学 | Traditional Chinese medicine preparation for treatment of neuroglioma |
| CN113397014A (en) * | 2021-06-29 | 2021-09-17 | 深圳市三也生物科技有限公司 | Preparation method of health tea granules |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416842A (en) * | 2001-10-30 | 2003-05-14 | 上海中西药业股份有限公司 | Liver protecting compound prepn and its prepn process |
-
2014
- 2014-01-20 CN CN201410024819.1A patent/CN103735736B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416842A (en) * | 2001-10-30 | 2003-05-14 | 上海中西药业股份有限公司 | Liver protecting compound prepn and its prepn process |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104474171A (en) * | 2014-11-17 | 2015-04-01 | 辛振学 | Traditional Chinese medicine preparation for treatment of neuroglioma |
| CN113397014A (en) * | 2021-06-29 | 2021-09-17 | 深圳市三也生物科技有限公司 | Preparation method of health tea granules |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103735736B (en) | 2016-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463554B (en) | A kind of treat malignant tumor pharmaceutical composition and preparation method and purposes | |
| CN103735736A (en) | Preparation method of liver-soothing tablet and application | |
| CN104857436B (en) | Traditional Chinese medicine compound composition with resisting liver cancer activity and its preparation method and application | |
| CN102784244B (en) | Externally applied traditional Chinese medicine for treating breast lumps | |
| CN103919966B (en) | A kind of medicine treating acne | |
| CN105617062A (en) | Traditional Chinese medicine composition used for treating lung cancer, and preparation method and applications thereof | |
| CN102008563B (en) | Anticancer traditional Chinese medicine and preparation method thereof | |
| CN107854656A (en) | A kind of Chinese traditional medicines depressing lipid composition and its production and use | |
| CN106511838A (en) | Traditional Chinese medicinal granules for treating alcoholic liver injury | |
| CN107375829A (en) | Treat the Chinese medicine composition of Post-apoplectic and its preparation method of preparation | |
| CN106974981A (en) | A kind of external used medicine of analgesic | |
| CN105853618A (en) | Traditional Chinese medicine composition with broad-spectrum anti-cancer effect as well as preparation method and application thereof | |
| CN104887775A (en) | Traditional Chinese medicine preparation for treating neonatal scleredema and preparation method therefor | |
| CN100382818C (en) | Prepn process of Chinese medicine and its coated tablet for treating cystic mastoproliferation and mastitis | |
| CN100478019C (en) | Medicinal pill, watered pill, honeyed pill for treating liver cancer and method for preparing same | |
| CN100478018C (en) | A medicine for treating liver cancer and method for preparing same | |
| CN102138947B (en) | Propolis Chinese medicinal composition | |
| CN102309630A (en) | Processing method for toxicity reduction and efficacy enhancement of rhizoma alismatis | |
| CN107184912A (en) | The positive disperse accumulations compound preparation of one breeding and its application | |
| CN102743480B (en) | Traditional Chinese medicine preparation for treating hepatitis and preparation method thereof | |
| CN103191197B (en) | Targeting formula antitumor anticancer agent and preparation method thereof | |
| CN101693096A (en) | Medicament for treating liver cancer and preparation method thereof | |
| CN107468949B (en) | Traditional Chinese medicine composition for treating advanced primary liver cancer and preparation method thereof | |
| CN106924330A (en) | A kind of application of Aidi preparation in anti-MPM medicine is prepared | |
| CN105998912A (en) | Traditional Chinese medicine weight losing composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |